Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1926
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab ; day:13 ; month:2 ; year:2019 ; pages:1-16
Clinical pharmacokinetics ; (13.2.2019), 1-16
- Creator
-
Wijnsma, Kioa Lente
Heine, Rob ter
Moes, Dirk Jan A. R.
Langemeijer, Saskia
Schols, Saskia E. M.
Volokhina, Elena. B.
den Heuvel, Lambertus P. van
Wetzels, Jack F. M.
Kar, Nicole C. A. J. van de
Brüggemann, Roger J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40262-019-00742-8
- URN
-
urn:nbn:de:101:1-2019031520313494964850
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wijnsma, Kioa Lente
- Heine, Rob ter
- Moes, Dirk Jan A. R.
- Langemeijer, Saskia
- Schols, Saskia E. M.
- Volokhina, Elena. B.
- den Heuvel, Lambertus P. van
- Wetzels, Jack F. M.
- Kar, Nicole C. A. J. van de
- Brüggemann, Roger J.
- SpringerLink (Online service)
Other Objects (12)
Treating C3 glomerulopathy with eculizumab
Treating C3 glomerulopathy with eculizumab
Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab
Eculizumab versus rituximab in generalised myasthenia gravis
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
The use of eculizumab in gemcitabine induced thrombotic microangiopathy
Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan
Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome
Treating C3 glomerulopathy with eculizumab
Treating C3 glomerulopathy with eculizumab
Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab
Eculizumab versus rituximab in generalised myasthenia gravis
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
The use of eculizumab in gemcitabine induced thrombotic microangiopathy
Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan
Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome
Treating C3 glomerulopathy with eculizumab
Treating C3 glomerulopathy with eculizumab
Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab
Eculizumab versus rituximab in generalised myasthenia gravis
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
The use of eculizumab in gemcitabine induced thrombotic microangiopathy
Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan